{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:27:03Z","timestamp":1791678423558,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ejim.2021.08.020","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T02:31:33Z","timestamp":1630290693000},"page":"39-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6343-3271","authenticated-orcid":false,"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-7586","authenticated-orcid":false,"given":"Federica","family":"Portunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Briano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele R.","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-5812","authenticated-orcid":false,"given":"Chiara","family":"Dentone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Robba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Loconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3600-193X","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Patroniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Dettori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pelosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ejim.2021.08.020_bib0002","series-title":"Clinical characteristics, management and in-hospital mortality of patients with COVID-19","author":"Vena","year":"2020"},{"key":"10.1016\/j.ejim.2021.08.020_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhin.2020.03.003","article-title":"Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection: a question needing an answer","author":"Lombardi","year":"2020","journal-title":"J Hospital Infect [Internet]"},{"issue":"8","key":"10.1016\/j.ejim.2021.08.020_bib0004","article-title":"Tocilizumab and steroid treatment in patients with COVID-19 pneumonia","volume":"15","author":"Mikulska","year":"2020","journal-title":"PLoS ONE [Internet]"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology [Oxford]"},{"key":"10.1016\/j.ejim.2021.08.020_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13319","article-title":"Bloodstream infections in critically ill patients with COVID-19","author":"Giacobbe","year":"2020","journal-title":"Eur J Clin Invest [Internet]"},{"key":"10.1016\/j.ejim.2021.08.020_bib0007","unstructured":"Bhimraj A et\u00a0al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection. Available from: https:\/\/www.idsociety.org\/COVID19guidelines."},{"key":"10.1016\/j.ejim.2021.08.020_bib0008","article-title":"Dexamethasone in Hospitalized Patients with COVID-19 - Preliminary Report","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejim.2021.08.020_bib0009","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2021.08.020_bib0011","series-title":"Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia [Internet]","author":"Rosas","year":"2020"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.ejim.2021.08.020_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2020.10.036","article-title":"Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis","volume":"27","author":"Tleyjeh","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ejim.2021.08.020_bib0014","article-title":"Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation","volume":"12","author":"Della-Torre","year":"2021","journal-title":"Front Immunol [Internet]"},{"issue":"4","key":"10.1016\/j.ejim.2021.08.020_bib0015","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"Cavalli","year":"2021","journal-title":"The Lancet Rheumatol [Internet]"},{"key":"10.1016\/j.ejim.2021.08.020_bib0016","unstructured":"RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et\u00a0al. Tocilizumab in patients admitted to hospital with COVID-19 [RECOVERY]: preliminary results of a randomised, controlled, open-label, platform trial [Internet]. Infectious Diseases [except HIV\/AIDS]; 2021 Feb [cited 2021 Feb 21]. Available from: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2021.02.11.21249258."},{"key":"10.1016\/j.ejim.2021.08.020_bib0017","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.08.020_bib0018","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2021.08.020_bib0019","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","author":"Salama","year":"2020","journal-title":"N Engl J Med [Internet]"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/s10165-008-0111-7","article-title":"Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0021","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/microorganisms8050695","article-title":"Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry [SMACORE]","volume":"8","author":"Colaneri","year":"2020","journal-title":"Microorganisms [Internet]"},{"issue":"10","key":"10.1016\/j.ejim.2021.08.020_bib0022","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"Biran","year":"2020","journal-title":"The Lancet Rheumatol [Internet]"},{"issue":"3","key":"10.1016\/j.ejim.2021.08.020_bib0023","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/joim.13162","article-title":"Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study","volume":"289","author":"Eimer","year":"2021","journal-title":"J Intern Med [Internet]"},{"key":"10.1016\/j.ejim.2021.08.020_bib0024","unstructured":"Infectious Diseases Society of America [IDSA]. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 [Internet]. Available from: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/."},{"issue":"6","key":"10.1016\/j.ejim.2021.08.020_bib0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.ejim.2021.08.020_bib0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock [Sepsis-3]","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA [Internet]"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmi.2019.07.007","article-title":"When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit","volume":"26","author":"Denny","year":"2020","journal-title":"Clin Microbiol Infect [Internet]"},{"issue":"12","key":"10.1016\/j.ejim.2021.08.020_bib0028","article-title":"Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis","volume":"8","author":"Petel","year":"2018","journal-title":"BMJ Open [Internet]"},{"issue":"10","key":"10.1016\/j.ejim.2021.08.020_bib0029","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00134-015-3978-8","article-title":"Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting","volume":"41","author":"Albrich","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ejim.2021.08.020_bib0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/21505594.2016.1158359","article-title":"Bloodstream infections in HIV-infected patients","volume":"7","author":"Taramasso","year":"2016","journal-title":"VIRULENCE"},{"key":"10.1016\/j.ejim.2021.08.020_bib0031","series-title":"Exploring Complexity in Health: An Interdisciplinary Systems Approach","first-page":"45-45","article-title":"Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?","author":"Taramasso","year":"2017"},{"issue":"7","key":"10.1016\/j.ejim.2021.08.020_bib0032","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0033","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis [Internet]"},{"key":"10.1016\/j.ejim.2021.08.020_bib0034","unstructured":"CDC. Pneumonia [Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]] Event [Internet]. Available from: https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/6pscvapcurrent.pdf."},{"issue":"4","key":"10.1016\/j.ejim.2021.08.020_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10040555","article-title":"Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study","volume":"10","author":"Giacobbe","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2021.08.020_bib0036","unstructured":"ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use. HIGHLIGHTS OF PRESCRIBING INFORMATION [Internet]. Available from: https:\/\/www.idsociety.org\/COVID19guidelineshttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf."},{"issue":"9","key":"10.1016\/j.ejim.2021.08.020_bib0037","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e318295a3d0","article-title":"Procalcitonin: a marker of infection not subverted by treatment with interleukin-6 receptor inhibition","volume":"32","author":"Gaensbauer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0038","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","article-title":"Sepsis and septic shock","volume":"2","author":"Hotchkiss","year":"2016","journal-title":"Nat Rev Dis Primers [Internet]"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0039","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2016.1164690","article-title":"The use and risks of antibiotics in critically ill patients","volume":"15","author":"Denny","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.ejim.2021.08.020_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9010095","article-title":"Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?","volume":"9","author":"Magnasco","year":"2021","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.ejim.2021.08.020_bib0041","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1186\/1364-8535-17-1001","article-title":"Unrevealing culture-negative severe sepsis","volume":"17","author":"de Prost","year":"2013","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.ejim.2021.08.020_bib0042","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/QCO.0b013e32835ebbd0","article-title":"Diagnosis of ventilator-associated pneumonia: controversies and working toward a gold standard","volume":"26","author":"Grgurich","year":"2013","journal-title":"Curr Opin Infect Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521002934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521002934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:59Z","timestamp":1760607299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521002934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"alternative-id":["S0953620521002934"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}